RU2004118423A - Производные бензотиазола в качестве лигандов рецептора аденозина - Google Patents
Производные бензотиазола в качестве лигандов рецептора аденозина Download PDFInfo
- Publication number
- RU2004118423A RU2004118423A RU2004118423/04A RU2004118423A RU2004118423A RU 2004118423 A RU2004118423 A RU 2004118423A RU 2004118423/04 A RU2004118423/04 A RU 2004118423/04A RU 2004118423 A RU2004118423 A RU 2004118423A RU 2004118423 A RU2004118423 A RU 2004118423A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- compounds
- formula
- alkyl
- morpholin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (19)
1. Соединения общей формулы
где R означает фенил, пиридин-2-ил, -С(O)-O-(низш.)алкил, -С(O)-(низш.)алкил, -С(O)-морфолинил, -C(O)-NR'2, -(CH2)n-NR'2 или -(СН2)n-O-(низш.)алкил, а R' означает водород или (низш.)алкил, и их фармацевтически приемлемые кислотно-аддитивные соли.
2. Соединения формулы I по п.1, где R означает фенил.
3. Соединения формулы I по п.2, где соединение означает (4-метокси-7-морфолин-4-илбензотиазол-2-ил)амид 1-бензил-2-оксо-1,2-дигидропиридин-4-карбоновой кислоты.
4. Соединения по п.1, где R означает -С(O)O-(низш.)алкил.
5. Соединения по п.4, где соединение означает этиловый эфир [4-(4-метокси-7-морфолин-4-илбензотиазол-2-илкарбамоил)-2-оксо-2Н-пиридин-1-ил]уксусной кислоты.
6. Соединения по п.1, где R означает -С(O)-(низш,)алкил.
7. Соединения по п.6, где соединение означает (4-метокси-7-морфолин-4-илбензотиазол-2-ил)амид 2-оксо-1-(2-оксобутил)-1,2-дигидропиридин-4-карбоновой кислоты.
8. Соединения по п.1, где R означает пиридинил.
9. Соединения по п.8, где соединение означает (4-метокси-7-морфолин-4-илбензотиазол-2-ил)амид 2-оксо-1-ïиридин-2-илметил-1,2-дигидропиридин-4-карбоновой кислоты.
10. Соединения по п.1, где R означает -С(O)-морфолинил.
11. Соединения по п.10, где соединение означает (4-метокси-7-морфолин-4-илбензотиазол-2-ил)амид 1-(2-морфолин-4-ил-2-оксоэтил)-2-оксо-1,2-дигидропиридин-4-карбоновой кислоты.
12. Соединения по п.1, где R означает -C(O)-NR'2.
13. Соединения по п.12, где соединение означает (4-метокси-7-морфолин-4-илбензотиазол-2-ил)амид 1-диметилкарбамоилметил-2-оксо-1,2-дигидропиридин-4-карбоновой кислоты.
14. Способ получения соединения формулы I по пп.1-13, включающий
а) взаимодействие соединения формулы
с соединением формулы
с образованием соединения формулы
где R означает фенил, пиридил, -С(O)O-(низш.)алкил или -С(O)-(низш.)алкил, или
б) взаимодействие соединения формулы
с соединением формулы
с образованием соединения формулы
где R означает -С(O)-морфолинил, -(СН2)n-O-(низш.)алкил, -(CH2)nNR'2 или -C(O)NR'2, и
при необходимости превращение полученных соединений в фармацевтически приемлемые кислотно-аддитивные соли.
15. Соединение по любому из пп.1-13, полученное способом по п.14 или эквивалентным способом.
16. Лекарственное средство, содержащее одно или более соединений по любому из пп.1-13 и фармацевтически приемлемые эксципиенты.
17. Лекарственное средство по п.16 для лечения заболеваний, опосредованных рецептором аденозина.
18. Применение соединения по любому из пп.1-13 для лечения заболеваний.
19. Применение соединения по любому из пп.1-13 для получения соответствующих лекарственных препаратов, предназначенных для лечения заболеваний, опосредованных аденозиновым рецептором А2A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01127313 | 2001-11-19 | ||
| EP01127313.3 | 2001-11-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004118423A true RU2004118423A (ru) | 2006-01-10 |
| RU2295523C2 RU2295523C2 (ru) | 2007-03-20 |
Family
ID=8179264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004118423/04A RU2295523C2 (ru) | 2001-11-19 | 2002-11-09 | Производные бензотиазола в качестве лигандов рецептора аденозина и лекарственное средство |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6599901B1 (ru) |
| EP (1) | EP1448196B1 (ru) |
| JP (1) | JP4216192B2 (ru) |
| KR (1) | KR100577109B1 (ru) |
| CN (1) | CN100346792C (ru) |
| AR (1) | AR037528A1 (ru) |
| AT (1) | ATE306265T1 (ru) |
| AU (1) | AU2002366194B8 (ru) |
| BR (1) | BR0214221A (ru) |
| CA (1) | CA2467551A1 (ru) |
| DE (1) | DE60206652T2 (ru) |
| ES (1) | ES2249639T3 (ru) |
| GT (1) | GT200200233A (ru) |
| MX (1) | MXPA04004683A (ru) |
| PA (1) | PA8557901A1 (ru) |
| PE (1) | PE20030715A1 (ru) |
| PL (1) | PL369470A1 (ru) |
| RU (1) | RU2295523C2 (ru) |
| TW (1) | TW200407137A (ru) |
| UY (1) | UY27543A1 (ru) |
| WO (1) | WO2003043634A1 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| JP4708795B2 (ja) | 2002-12-20 | 2011-06-22 | ニコノヴァム エービー | 物理的および化学的に安定なニコチン−含有粒状物質 |
| KR20060058132A (ko) | 2003-09-19 | 2006-05-29 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 리간드로서의 싸이아졸로피리딘 유도체 |
| US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| ATE457986T1 (de) * | 2004-07-22 | 2010-03-15 | Hoffmann La Roche | Benzothiazolderivate |
| BRPI0513510A (pt) * | 2004-07-22 | 2008-05-06 | Hoffmann La Roche | benzotiazóis substituìdos |
| ES2273599B1 (es) * | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| AU2007322269A1 (en) * | 2006-10-11 | 2008-05-29 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
| PT2144905E (pt) * | 2007-04-04 | 2013-02-26 | Merck Sharp & Dohme | Agentes terapêuticos |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CA3007673A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| EP4293009A3 (en) | 2015-12-22 | 2024-02-21 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
| US20180055789A1 (en) | 2016-08-24 | 2018-03-01 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht2b agonists and methods of using same |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3806835A1 (en) * | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| DE102019110904B4 (de) | 2019-04-26 | 2022-01-20 | Helmholtz-Zentrum Dresden - Rossendorf E. V. | N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3374550D1 (en) | 1982-12-21 | 1987-12-23 | Johnsen Jorgensen Plastics Ltd | Dispensing container |
| IL153278A0 (en) * | 2000-06-21 | 2003-07-06 | Hoffmann La Roche | Benzothiazole derivatives |
-
2002
- 2002-11-05 US US10/288,531 patent/US6599901B1/en not_active Expired - Fee Related
- 2002-11-09 BR BR0214221-0A patent/BR0214221A/pt not_active IP Right Cessation
- 2002-11-09 MX MXPA04004683A patent/MXPA04004683A/es active IP Right Grant
- 2002-11-09 ES ES02803360T patent/ES2249639T3/es not_active Expired - Lifetime
- 2002-11-09 RU RU2004118423/04A patent/RU2295523C2/ru not_active IP Right Cessation
- 2002-11-09 AT AT02803360T patent/ATE306265T1/de not_active IP Right Cessation
- 2002-11-09 KR KR1020047007646A patent/KR100577109B1/ko not_active IP Right Cessation
- 2002-11-09 WO PCT/EP2002/012543 patent/WO2003043634A1/en active IP Right Grant
- 2002-11-09 JP JP2003545315A patent/JP4216192B2/ja not_active Expired - Fee Related
- 2002-11-09 AU AU2002366194A patent/AU2002366194B8/en not_active Ceased
- 2002-11-09 DE DE60206652T patent/DE60206652T2/de not_active Expired - Fee Related
- 2002-11-09 CN CNB028228901A patent/CN100346792C/zh not_active Expired - Fee Related
- 2002-11-09 PL PL02369470A patent/PL369470A1/xx not_active Application Discontinuation
- 2002-11-09 CA CA002467551A patent/CA2467551A1/en not_active Abandoned
- 2002-11-09 EP EP02803360A patent/EP1448196B1/en not_active Expired - Lifetime
- 2002-11-14 TW TW091133382A patent/TW200407137A/zh unknown
- 2002-11-14 PA PA20028557901A patent/PA8557901A1/es unknown
- 2002-11-15 PE PE2002001103A patent/PE20030715A1/es not_active Application Discontinuation
- 2002-11-15 AR ARP020104398A patent/AR037528A1/es not_active Application Discontinuation
- 2002-11-18 UY UY27543A patent/UY27543A1/es not_active Application Discontinuation
- 2002-11-18 GT GT200200233A patent/GT200200233A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60206652D1 (de) | 2006-02-23 |
| JP2005515980A (ja) | 2005-06-02 |
| DE60206652T2 (de) | 2006-06-22 |
| AU2002366194B8 (en) | 2006-11-16 |
| PL369470A1 (en) | 2005-04-18 |
| GT200200233A (es) | 2003-06-17 |
| PA8557901A1 (es) | 2003-06-30 |
| AU2002366194B2 (en) | 2006-10-26 |
| ES2249639T3 (es) | 2006-04-01 |
| AU2002366194A1 (en) | 2003-06-10 |
| TW200407137A (en) | 2004-05-16 |
| KR20050044537A (ko) | 2005-05-12 |
| JP4216192B2 (ja) | 2009-01-28 |
| UY27543A1 (es) | 2003-05-30 |
| PE20030715A1 (es) | 2003-08-29 |
| US6599901B1 (en) | 2003-07-29 |
| CN100346792C (zh) | 2007-11-07 |
| AR037528A1 (es) | 2004-11-17 |
| RU2295523C2 (ru) | 2007-03-20 |
| BR0214221A (pt) | 2004-09-21 |
| CA2467551A1 (en) | 2003-05-30 |
| ATE306265T1 (de) | 2005-10-15 |
| CN1589146A (zh) | 2005-03-02 |
| EP1448196B1 (en) | 2005-10-12 |
| EP1448196A1 (en) | 2004-08-25 |
| KR100577109B1 (ko) | 2006-05-10 |
| MXPA04004683A (es) | 2004-08-12 |
| WO2003043634A1 (en) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004118423A (ru) | Производные бензотиазола в качестве лигандов рецептора аденозина | |
| SU1349698A3 (ru) | Способ получени производных пиримидин-2-онов или их солей | |
| JPH0613484B2 (ja) | 新規なジヒドロピリミジン類 | |
| RU2007128987A (ru) | 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры | |
| RU2001122114A (ru) | 4-(гетероциклилсульфонамидо)-5-метокси-6-(2-метоксифенокси)-2-фенил- или пиридилпиримидины в качестве антагонистов рецептора эндотелина | |
| RU2006130684A (ru) | Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов | |
| RU2006110186A (ru) | Алкокси замещенные имидазохинолины | |
| RU2007130802A (ru) | Пуриновые производные в качестве агонистов рецептора а2а | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| RU2003116648A (ru) | Замещенные имидазопиридины | |
| RU2007106928A (ru) | Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы | |
| RU2004119438A (ru) | Производные бензотиазола | |
| ES2427894T3 (es) | Aza-indoles y compuestos relacionados que tienen actividad biológica antagonista del receptor de esfingosina-1-fosfato (S1P) | |
| RU2002131885A (ru) | Антраниламиды и их применение в качестве лекарственных средств | |
| TWI815887B (zh) | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 | |
| JP2005538111A5 (ru) | ||
| JP2004525178A5 (ru) | ||
| RU98117245A (ru) | 2-(арилфенил)аминоимидазолиновые производные | |
| US4414213A (en) | Dihydropyridyl cyclic imidate esters and their pharmaceutical use | |
| RU2003130644A (ru) | Производные ркарболина и их фармацевтическое применение против дипрессии и страха | |
| CA2370830A1 (en) | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | |
| RU2005128793A (ru) | Химические соединения | |
| KR930000483A (ko) | [(아릴알킬피페리딘-4-일)메틸]-2a,3,4,5-테트라 하이드로-1(2H)-아세나프틸렌-1-온 및 관련 화합물, 이의 제조방법 및 약제로서의 이의 용도 | |
| RU2004107847A (ru) | Изоксазолпиридиноны и их применение в лечении болезни паркинсона | |
| JP2002529497A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20091110 |